Pluri Inc. is a biotechnology company. Its technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of medicine and climate change to food scarcity, animal cruelty and beyond. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is based in HAIFA, Israel.
| Revenue (Most Recent Fiscal Year) | $1.34M |
| Net Income (Most Recent Fiscal Year) | $-22.58M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 18.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1740.64% |
| Net Margin (Trailing 12 Months) | -1701.19% |
| Return on Equity (Trailing 12 Months) | -4191.91% |
| Return on Assets (Trailing 12 Months) | -88.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 51.65 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 8.16M |
| Free Float | 6.04M |
| Market Capitalization | $34.66M |
| Average Volume (Last 20 Days) | 9416.05 |
| Beta (Past 60 Months) | 0.66 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.93% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.59% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |